DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information

Lade...
Vorschaubild
Dateien
Amelio_2-1vc2qm7jgams93.pdf
Amelio_2-1vc2qm7jgams93.pdfGröße: 898.1 KBDownloads: 27
Datum
2014
Autor:innen
Gostev, Mikhail
Knight, Richard A.
Willis, Anne E.
Melino, Gerry
Antonov, Alexey V.
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
ArXiv-ID
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Open Access Gold
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Cell death & disease. Nature Publishing Group. 2014, 5, e1051. eISSN 2041-4889. Available under: doi: 10.1038/cddis.2014.9
Zusammenfassung

The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
drug repositioning, clinical trial design, patient survival, thioridazine
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690AMELIO, Ivano, Mikhail GOSTEV, Richard A. KNIGHT, Anne E. WILLIS, Gerry MELINO, Alexey V. ANTONOV, 2014. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. In: Cell death & disease. Nature Publishing Group. 2014, 5, e1051. eISSN 2041-4889. Available under: doi: 10.1038/cddis.2014.9
BibTex
@article{Amelio2014-02-06DRUGS-57119,
  year={2014},
  doi={10.1038/cddis.2014.9},
  title={DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information},
  volume={5},
  journal={Cell death & disease},
  author={Amelio, Ivano and Gostev, Mikhail and Knight, Richard A. and Willis, Anne E. and Melino, Gerry and Antonov, Alexey V.},
  note={Article Number: e1051}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/57119">
    <dc:contributor>Antonov, Alexey V.</dc:contributor>
    <dc:creator>Antonov, Alexey V.</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:creator>Melino, Gerry</dc:creator>
    <dc:creator>Amelio, Ivano</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/57119/3/Amelio_2-1vc2qm7jgams93.pdf"/>
    <dcterms:issued>2014-02-06</dcterms:issued>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Knight, Richard A.</dc:creator>
    <dc:creator>Gostev, Mikhail</dc:creator>
    <dcterms:title>DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information</dcterms:title>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Knight, Richard A.</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Willis, Anne E.</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/57119"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-03-31T12:59:57Z</dcterms:available>
    <dc:creator>Willis, Anne E.</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/57119/3/Amelio_2-1vc2qm7jgams93.pdf"/>
    <dc:contributor>Gostev, Mikhail</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-03-31T12:59:57Z</dc:date>
    <dc:language>eng</dc:language>
    <dc:contributor>Amelio, Ivano</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Melino, Gerry</dc:contributor>
    <dcterms:abstract xml:lang="eng">The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.</dcterms:abstract>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Ja
Diese Publikation teilen